Abstract
Mast cell activation syndrome (MCAS) involves the skin, gastrointestinal, cardiovascular, respiratory, and neurologic systems, classified as primary, secondary, and idiopathic. Earlier criteria for MCAS diagnosis included episodic symptoms with mast cell mediators affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope, tachycardia, wheezing, conjunctival injection, pruritus, nasal stuffiness, decrease in frequency, severity, or resolution of symptoms with anti-mediator therapy including H1/H2 receptor antagonists, anti-leukotrienes, or mast cell stabilizers. Laboratory data includes an increased validated urinary or serum markers of MCAS, documentation of an increase of the marker above the patient’s baseline value during symptomatic periods on more than two occasions, or baseline serum tryptase levels that are persistently above 15 ng/mL. Laboratory data also includes an increase of the tryptase level above baseline value on one occasion. Other assays are 24-h urine histamine metabolites, PGD2 or its metabolite, and 11-β-prostaglandin F2 alpha. A recent global classification is a response of clinical symptoms, a substantial transient increase in serum total tryptase or increase in other mast cell-derived mediators, histamine or PGD2 or urinary metabolites, and agents that attenuate production or mast cell mediator activities. “Spectrum of MCAS disorders” has been proposed, highlighting symptoms’ diagnostic tests and treatments.
Similar content being viewed by others
References
Kinet J-P (1990) The high affinity receptor for IgE. Curr Opin Immunol 2:499–505
Cambier JC (1995) Antigen and Fc receptor signaling: the awesome power of the immunoreceptor tyrosine based activation motif (ITAM). J Immunol 155:3281–5
Fukamachi H, Kawakami Y, Takei M et al (1992) Association of protein tyrosine kinase with phospholipase C-γ1 in bone marrow-derived mouse mast cells. Proc Natl Acad Sci U S A 89:9524–8
Bischoff SC, Dahinden CA (1992) c-Kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 175:237–44
Galli SJ, Tsai M, Wershil BK (1993) The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 142(4):965–74
Galli SJ, Zsebo KM, Geissler EN (1994) The kit ligand, stem cell factor. Adv Immunol 55:1–96
Lukacs NW, Strieter RM, Lincoln PM et al (1996) Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation. J Immunol 156(10):3945–51
Bingham CO III, Austen KF (2000) Mast-cell responses in the development of asthma. J Allergy Clin Immunol 105(2 Pt 2):S527–34
Iemura A, Tsai M, Ando A et al (1994) The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 144(2):321–8
Horny HP, Sotlar K, Valent P (2012) Evaluation of mast cell activation syndromes: impact of pathology and immunohistology. Int Arch Allergy Immunol 159(1):1–5
Meninger CJ, Yano H, Rottapel R et al (1992) The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 4:958–63
Ito T, Smrž D, Jung MY et al (2012) Stem cell factor programs the mast cell activation phenotype. J Immunol 188(11):5428–37
Gilfillan AM, Rivera J (2009) The tyrosine kinase network regulating mast cell activation. J Immunol Rev Immunol Rev 228(1):149–69
Akin C, Valent P, Metcalfe DD (2010) Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 126:1099–1104
Akin C (2014) Mast cell activation disorders. J Allergy Clin Immunol Pract 2:252–57
Shibao C, Arzubiaga C, 2nd Roberts LJ et al (2005) Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 45(3):385–90
Naysan J, Kodsi S, Kristal L (2013) Solitary mastocytoma of the eyelid. J AAPOS 17(4):433–434
Auquit-Auckbur I, Lazar C, Deneuve S et al (2012) Malignant transformation of mastocytoma developed on skin mastocytosis into cutaneous mast cell sarcoma. Am J Surg Pathol 36(5):779–82
Falleti J, Borgia L, Lalinga AV et al (2012) Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis? Pathol Res Pract 208(11):683–6
Frieri M (2009) Mastocytosis. Challenging cases in allergy and immunology Ed: Massoud Mahmoudi Chapter 14. pp201-212. Humana Press
Akin C, Scott LM, Kocabas CN et al (2007) Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood 110:2331–3
Koterba AP, Akin C (2008) Differences in the clinical presentation of anaphylaxis in patients with indolent systemic mastocytosis (ISM) versus idiopathic anaphylaxis (IA). J Allergy Clin Immunol 121:S68a, abstract
Greenberger P, Lieberman P (2014) Idiopathic anaphylaxis. J Allergy Clin Immunol 2:243–250, In Practice Issue #3
Lieberman P et al (2005) An updated practice parameter EdsIdiopathic anaphylaxis. Diagnosis Manage Anaphylaxis 115(3):S483–S523
Valent P, Akin C, Arock M et al (2012) Definitions, criteria & global classification of MC disorders with special reference to MCAS: a consensus proposal. Int Arch Allergy Immunol 157(3):215–25
Alvarez-Twose I, de González OD, Sánchez-Muñoz L et al (2010) Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 125(6):1269–1278
Frieri M (2009) Anaphylaxis. Chapter 68, pp721-730. In: Manual of Critical Care, Philadelphia, Pa. American College of Physicians
Matito A, Alvarez-Twose I, Morgado JM et al (2014) Anaphylaxis as a clinical manifestation of clonal mast cell disorders. Curr Allergy Asthma Rep 14(8):450
Hamilton MJ, Hornick JL, Akin C et al (2011) A newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 128(1):147–152
Metcalfe DD (2000) Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy Asthma Proc 21(1):21–24
Lafont E et al (2014) Causes and diffential diagnosis of flush. Rev Med Interne 35(5):303–9
Picard M, Giavina-Bianchi P, Mezzano V et al (2013) Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther 35(5):548–62
Pardanani A (2012) Systemic mastocytosis in adults. Update on diagnosis, risk stratification, and management. Am J Hematol 87(4):401–11
Frieri M, Linn N, Schweitzer M, Angadi C et al (1990) Lymphadenopathic mastocytosis with eosinophilia and biclonal gammopathy. J Allergy Clin Immuno 86:l26–132
Gotlib J, Akin C (2012) Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. Semin Hematol 49(2):128–37
Bai Y, Bandara G, Ching Chan E (2012) Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia 27(2):278–85
Bax HJ, Keeble AH, Gould HJ (2012) Cytokinergic IgE action in mast cell activation. Frontiers Immunol Inflamm Vol 3:229
Patel R, Celestin J, Frieri M (2012) An unusual case of mast cell activation syndrome. J Allergy Clin Immunol;, abs #475
Afrin LB (2012) Mast cell activation syndrome masquerading as agranulocytosis. Mil Med 177(1):113–7
Kritas SK, Saggini A, Varvara G et al (2013) Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 27(3):655–60
Frieri M, Agarwal K, Datar A, Trotta P (1994) Increased interleukin-4 production in response to mast cell mediators and human type I collagen in patients with rheumatoid arthritis. Ann Allergy 72:1–8
Afrin LB (2012) Sclerosing mediastinitis and mast cell activation syndrome. Pathol Res Pract 208(3):181–5
Hawrylko E, Spertus A, Mele C et al (1991) Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis. Arthritis Rheum 34:580
Frieri M (1992) Systemic sclerosis. The role of the mast cell and cytokines. Ann Allergy 69:385–397
Frieri M (1993) Systemic sclerosis and related antinuclear antibody serologies. Immunopath; 17:#5, IP 93–5, 1–9
Frieri M, Patel R, Celestin J (2013) Mast cell activation syndrome: a review. Curr Allergy Asthma Rep 13(1):27–32
Frieri M, Quershi M (2013) Pediatric mastocytosis. Review of the literature. Ped Allergy Asthma Pulmonol 26(#4):175–180
Cardet JC, Castells MC, Hamilton MJ (2013) Immunology & clinical manifestations of non-clonal MCAS. Curr Allergy Asthma Rep 13(1):10–8
Jennings S, Russell N, Jennings B et al (2014) The mastocytosis society survey on mast cell disorders: patient experiences and perception. J Allergy Clin Immunol Pract 2:70–6
Bell MC, Jackson DJ (2012) Anaphylaxis prevention related to MCAS with omalizumab letters. Ann Allergy Asthma Immunol 108(5):384–384
Sokol K, Ghazi A, Kelly BC et al (2014) Omalizumab as a desensitizing agent and treatment in mastocytosis. Rev Case Report J Allergy Clin Immunol Prac 2:266–758
Jagdis A, Vadas P (2014) Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Annals Allergy, Asthma Immunol 113(1):115–116
Petra A, Panagiotidou S, Stewart JM et al (2014) Spectrum of mast cell activation disorders. Expert Rev Clin Immunol 10(6):729–39
Brockow K (2014) Epidemiology, prognosis, risk factors in mastocytosis. Immunol Allergy Clin North Am 34(2):283–295
Yip HK, Kolesnikoff N, Yu C et al (2014) Mechanisms of vitamin D3 metabolite repression of IgE-dependent mast cell activation. J Allergy Clin Immunol 133(5):1356–64
Sabato V, Van De Vijver E, Hagendorens M et al (2014) Mast cell activation. Familial hypertryptasemia with associated mast cell activation syndrome. J Allergy Clin Immunol 133:1356–1364
Wiednig M, Beham-Schmid C, Kranzelbinder B et al (2013) Clonal mast cell proliferation in pruriginous skin in hypereosinophilic syndrome. Dermatology 227(1):67–71
Doyle LA, Sepehr GJ, Hamilton MJ et al (2014) A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol 38(6):832–43
Hwang S-L, Lu Y, Li X (2014) ERK1/2 antagonize AMPK-dependent regulation of FcεRI-mediated mast cell activation and anaphylaxis. J Allergy Clin Immunol 134:714–21
Schäfer D, Dreßen P, Brettner S et al (2014) Prostaglandin D2-supplemented “functional eicosanoid testing and typing” assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study. J Transl Med 12(1):213
Sibilano R, Frossi B, Pucillo CE (2014) Mast cell activation: a complex interplay of positive and negative signaling pathways. Eur J Immunol; Jul 27
Kounis NG, Mazarakis A, Almpanis G et al (2014) The more allergens an atopic patient is exposed to, the easier and quicker anaphylactic shock and Kounis syndrome appear: clinical and therapeutic paradoxes. J Nat Sci Biol Med 5(2):240–4
Alevizos M, Karagkouni A, Panagiotidou S et al (2014) Stress triggers coronary mast cells leading to cardiac events. Ann Allergy Asthma Immunol 112(4):309–16
Afrin LB (2013) Utility of hydroxyurea in mast cell activation syndrome. Exp Hematol Oncol 2(1):28
Afrin LB (2014) Mast cell activation syndrome as a significant comorbidity in sickle cell disease. Am J Med Sci; Aug 28
Gülen T, Hägglund H, Sander B et al (2014) The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy 44(9):1179–87
Lu Y, Li X, Park YN, Kwon O et al (2014) Britanin suppresses IgE/Ag-induced mast cell activation by inhibiting the Syk pathway. Biomol Ther (Seoul) 22(3):193–9
Akin C (2014) Mast cell activation disorders. J Allergy Clin Immunol Pract 2(3):252–7
Haenisch B, Fröhlich H, Herms S et al (2014) Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease. Immunogenetics 66(5):287–97
Ethical Statement
I have no grant support or any conflict of interest for this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Frieri, M. Mast Cell Activation Syndrome. Clinic Rev Allerg Immunol 54, 353–365 (2018). https://doi.org/10.1007/s12016-015-8487-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-015-8487-6